722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities

• Heather Kinkead,
• Chelsie Macedo,
• Angelica Sanabria,
• Rajay Pandit,
• Florian Sulzmaier,
• John Timmer,
• Brendan Eckelman,
• Analeah Heidt,
• Anya Polovina,
• Nadja Kern,
• Abrahim Hussain,
• Sae Jeong Ahn,
• William Crago

Affiliations

Heather Kinkead

Aff1 grid.21107.350000000121719311OncologyJohns Hopkins University Baltimore MD USA

Chelsie Macedo

Inhibrx, La Jolla, CA, United States

Angelica Sanabria

Inhibrx, La Jolla, CA, United States

Rajay Pandit

Inhibrx, La Jolla, CA, United States

Florian Sulzmaier

Inhibrx, La Jolla, CA, United States

John Timmer

Inhibrx, La Jolla, CA, United States

Brendan Eckelman

Inhibrx, La Jolla, CA, United States

Analeah Heidt

Inhibrx, La Jolla, CA, United States

Anya Polovina

Inhibrx Inc., La Jolla, CA, United States

Nadja Kern

Inhibrx Inc., La Jolla, CA, United States

Abrahim Hussain

Inhibrx Inc., La Jolla, CA, United States

Sae Jeong Ahn

Inhibrx Inc., La Jolla, CA, United States

William Crago

Inhibrx Inc., La Jolla, CA, United States